Wouter Meuleman is listed as a director on 2 SEC Form D filings by 1 issuer between Apr 2024 and Jun 2025: RedShift BioAnalytics, Inc. (Boxborough, MA — other technology — 2024–2025; $18.3M reported sold to 12 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Bryson Hollimon (2 shared filings), Frank Smith (2 shared filings), Thomas O'Lenic (2 shared filings), William Cadogan (2 shared filings), Amol Chaubal (1 shared filing) and 2 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Wouter. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Wouter Meuleman and found 2 differences: No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.